We next investigated the potential efficacy of SAH5-EJ1 in the mouse model of a patient-derived lung adenocarcinoma in which the patient had been treated with the HER1 specific TKI Erlotinib and had developed resistance (TM00784). The gene discussed is EGFR; the disease is lung adenocarcinoma.